Most policies still exclude weight-loss medications under general exclusions unless they are part of the treatment of a ...

The B.C. government is restricting the sales of two more diabetes drugs to people outside Canada amid rising demand for the ...

National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

PORTLAND, OR, UNITED STATES, July 17, 2025 /EINPresswire.com/ -- The global anti-obesity drugs market, valued at $1,605.36 million in 2022, is projected to reach $4,439.34 million by 2032, expanding ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Wegovy, India’s first injectable semaglutide for chronic weight management, recorded Rs 2.54 crore in sales in June ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the anti-diabetic medication.